kynostatin 272 has been researched along with kynostatin 227 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erickson, J; Ford, H; Gulnik, S; Hayashi, H; Kageyama, S; Mimoto, T; Murakawa, Y; Nomizu, M; Shirasaka, T; Takada, K | 1 |
| Fukazawa, T; Hayashi, H; Kato, R; Kiso, Y; Mimoto, T; Misawa, S; Nojima, S; Sato, H; Shintani, M; Takaku, H; Terashima, K; Ueno, T | 1 |
| Bader, JP; Cragg, GM; Newman, DJ; Yang, SS | 1 |
| Freire, E; Hayashi, Y; Hidaka, K; Kamiya, M; Kimura, T; Kiso, Y; Ruben, AJ; Tsuchiya, Y | 1 |
| Akaji, K; Enomoto, H; Hattori, N; Imai, J; Kisanuki, S; Kiso, Y; Mimoto, T | 1 |
| Kiriyama, A; Kisanuki, S; Kiso, Y; Mimoto, T; Takada, K | 1 |
| Itoh, E; Shibata, N; Terashima, S | 1 |
1 review(s) available for kynostatin 272 and kynostatin 227
| Article | Year |
|---|---|
Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program.
Topics: Amino Acid Sequence; Anti-HIV Agents; HIV-1; Models, Biological; Models, Chemical; Molecular Sequence Data; National Institutes of Health (U.S.); Retrospective Studies; United States; Virus Replication | 2001 |
6 other study(ies) available for kynostatin 272 and kynostatin 227
| Article | Year |
|---|---|
In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine.
Topics: Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Drug Resistance, Microbial; Gene Products, gag; HIV; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Oligopeptides; Phenylbutyrates; Protein Precursors; Protein Processing, Post-Translational; Radioimmunoprecipitation Assay; Zidovudine | 1993 |
Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine.
Topics: Administration, Oral; Animals; Biological Availability; Cell Line; Dipeptides; Dogs; Drug Evaluation, Preclinical; HIV Protease Inhibitors; HIV-1; Inhibitory Concentration 50; Injections, Intravenous; Oligopeptides; Phenylbutyrates; Rats; Structure-Activity Relationship; Thiazoles; Thiazolidines | 1999 |
Additional interaction of allophenylnorstatine-containing tripeptidomimetics with malarial aspartic protease plasmepsin II.
Topics: Animals; Antimalarials; Aspartic Acid Endopeptidases; Biomimetic Materials; Oligopeptides; Phenylbutyrates; Plasmodium falciparum; Protease Inhibitors; Protein Conformation; Protozoan Proteins; Structure-Activity Relationship | 2007 |
Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine.
Topics: Antiviral Agents; HIV Protease Inhibitors; HIV-1; Oligopeptides | 1992 |
Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations.
Topics: Animals; Biological Availability; Duodenum; Half-Life; HIV Protease Inhibitors; Injections, Intravenous; Intubation, Gastrointestinal; Male; Oligopeptides; Rats; Rats, Wistar | 1993 |
Practical synthesis of (2s,3s)-3-amino-2-hydroxy-4-phenylbutyric acid, a key component of HIV protease inhibitors.
Topics: Anti-HIV Agents; Carbamates; Furans; HIV Protease Inhibitors; Nitriles; Oligopeptides; Phenylbutyrates; Stereoisomerism; Sulfonamides | 1998 |